Identification of Small-Molecule Inducers of FOXP3 in Human T Cells Using High-Throughput Flow Cytometry

Application of High-Throughput Flow Cytometry in Early Drug Discovery: An AstraZeneca Perspective

“…This high-information content enables researchers to group (or gate ) cellular subpopulations phenotypically based on one or more of the observed parameters, expanding the power of analysis beyond gross population measures. There are numerous and diverse recent examples of cell-based and bead-based applications of HTFC in preclinical drug discovery, many of which take advantage of the subpopulation ability that flow cytometry provides (e.g., phenotypic screening of cytotoxic T-lymphocyte lytic granule exocytosis in a 1536-well format, 19 phenotypic screening of human primary T cells, 22,23 screening using fluorescent barcoded cells, 11,24 and screening of Rho GTPases using a bead-based assay 12 ).…”

“…In recent years, an increasing amount of reports have described diverse applications of different HTFC platforms using 96-, 384-, and 1536-well formats at various phases of drug discovery in pharma and biotech companies as well as in academic institutes. 3,8,10–33 These reports demonstrate that HTFC technology has played, and will continue to play, an important role in early drug discovery. This article describes the deployment of HTFC platforms within AstraZeneca and MedImmune to support our early drug discovery process from target identification (TI), through hit identification (HI) and lead identification (LI), to lead optimization (LO).…”